Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on July 28, 2003

Hypertension. 2003
Published online before print July 28, 2003, doi: 10.1161/01.HYP.0000085332.69777.D1
A more recent version of this article appeared on October 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
42/4/844    most recent
01.HYP.0000085332.69777.D1v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendez, M.
Right arrow Articles by LaPointe, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendez, M.
Right arrow Articles by LaPointe, M. C.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Other hypertension
Right arrow Gene expression
Right arrow Gene regulation
Right arrow Growth factors/cytokines
Right arrow Hypertrophy

Submitted on May 5, 2003
Revised on June 2, 2003

PPAR{gamma} Inhibition of Cyclooxygenase-2, PGE2 Synthase, and Inducible Nitric Oxide Synthase in Cardiac Myocytes

Mariela Mendez and Margot C. LaPointe*

From the Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Mich.

* To whom correspondence should be addressed. E-mail: mclapointe{at}aol.com.

Abstract--Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor superfamily. They regulate lipid metabolism, glucose homeostasis, cell proliferation, and differentiation and modulate inflammatory responses. We examined whether PPAR{gamma} is functional in cultured neonatal ventricular myocytes and studied its role in inflammation. Western blots revealed PPAR{gamma} in myocytes. When myocytes were transfected with a PPAR response element reporter plasmid (PPRE-TK-luciferase), the PPAR{gamma} activator 15-deoxy-{Delta}12,14-prostaglandin J2 (15dPGJ2) increased promoter activity, whereas cotransfection of a dominant negative PPAR{gamma} inhibited it. To determine the role of 15dPGJ2 in expression of proinflammatory genes, we tested its effect on interleukin-1{beta} induction of cyclooxygenase-2 (COX-2). 15dPGJ2 decreased interleukin-1{beta} stimulation of COX-2 by 40% and PGE2 production by 73%. We next questioned whether 15dPGJ2 was modulating the expression of inducible prostaglandin E2 synthase (PGES) and found that it completely blocked interleukin-1{beta} induction of PGES. Use of a second PPAR{gamma} agonist, troglitazone, and the selective PPAR{gamma} antagonist GW9662 demonstrated that the effects seen were PPAR{gamma}-dependent. In addition, we found that 15dPGJ2 blocked interleukin-1{beta} stimulation of inducible nitric oxide synthase (iNOS). We concluded that 15dPGJ2 may play an anti-inflammatory role in a PPAR{gamma}-dependent manner, decreasing COX-2, PGES, and PGE2 production, as well as iNOS expression.


Key words: myocytes • nitric oxide synthase • cyclooxygenase • prostaglandins




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
Y. Yuhas, E. Berent, R. Cohen, and S. Ashkenazi
Roles of NF-{kappa}B Activation and Peroxisome Proliferator-Activated Receptor Gamma Inhibition in the Effect of Rifampin on Inducible Nitric Oxide Synthase Transcription in Human Lung Epithelial Cells
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1539 - 1545.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. A. Konstantinopoulos, M. V. Karamouzis, and A. G. Papavassiliou
Effect of Aspirin Use on Thiazolidinediones and Cardiovascular Events
JAMA, April 2, 2008; 299(13): 1539 - 1539.
[Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
B. Samuelsson, R. Morgenstern, and P.-J. Jakobsson
Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target
Pharmacol. Rev., September 1, 2007; 59(3): 207 - 224.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Fu, Z. Wang, W. L. Chen, P. K. Moore, and Y. Z. Zhu
Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1545 - H1552.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. N. Finck
The PPAR regulatory system in cardiac physiology and disease
Cardiovasc Res, January 15, 2007; 73(2): 269 - 277.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ye, Y. Lin, S. Atar, M.-H. Huang, J. R. Perez-Polo, B. F. Uretsky, and Y. Birnbaum
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1158 - H1169.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman
Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats
FASEB J, June 1, 2006; 20(8): 1162 - 1175.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
P Froment, F Gizard, D Defever, B Staels, J Dupont, and P Monget
Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition.
J. Endocrinol., May 1, 2006; 189(2): 199 - 209.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S Soumian, R Gibbs, A Davies, and C Albrecht
mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease
J. Clin. Pathol., December 1, 2005; 58(12): 1255 - 1260.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Moon, W. C. Glasgow, and T. E. Eling
Curcumin Suppresses Interleukin 1{beta}-Mediated Microsomal Prostaglandin E Synthase 1 by Altering Early Growth Response Gene 1 and Other Signaling Pathways
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 788 - 795.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
E. B. E. Berry, J. A. Keelan, R. J. A. Helliwell, R. S. Gilmour, and M. D. Mitchell
Nanomolar and Micromolar Effects of 15-Deoxy-{Delta}12,14-prostaglandin J2 on Amnion-Derived WISH Epithelial Cells: Differential Roles of Peroxisome Proliferator-Activated Receptors {gamma} and {delta} and Nuclear Factor {kappa}B
Mol. Pharmacol., July 1, 2005; 68(1): 169 - 178.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
Z. Gong, D. Xie, Z. Deng, R. M. Bostick, S. J. Muga, T. G. Hurley, and J. R. Hebert
The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas
Carcinogenesis, March 1, 2005; 26(3): 579 - 585.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Shimazu, I. Inoue, N. Araki, Y. Asano, M. Sawada, D. Furuya, H. Nagoya, and J. H. Greenberg
A Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Reduces Infarct Size in Transient but Not in Permanent Ischemia
Stroke, February 1, 2005; 36(2): 353 - 359.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
F. J. Sanchez-Gomez, E. Cernuda-Morollon, K. Stamatakis, and D. Perez-Sala
Protein Thiol Modification by 15-deoxy-{Delta}12,14-Prostaglandin J2 Addition in Mesangial Cells: Role in the Inhibition of Pro-inflammatory Genes
Mol. Pharmacol., November 1, 2004; 66(5): 1349 - 1358.
[Abstract] [Full Text] [PDF]